To investigate the expression and their clinical significance of serum hypersensitive C-reactive protein (hs-CRP) and lactate dehydrogenase (LDH) in patients with acute leukemia (AL).

A total of 150 AL patients who were treated in Zhengzhou People’s Hospital from December 2013 to December 2019 were selected as the AL group, and 50 patients with healthy physical examination during the same period were selected as the control group. The serum hs-CRP and LDH levels in the initial treatment, remission, and recurrence phases of the two groups and the AL group were compared, and the 5-year survival rates of patients with different hs-CRP and LDH levels were analyzed.

The levels of hs-CRP and LDH in the AL group were higher than those in the control group (t=4.066, 14.110, P<0.05). The serum hs-CRP and LDH levels of patients in the initial treatment and recurrence phases of the AL group were higher than those in the remission phase (P<0.05); the serum hs-CRP and LDH levels of patients in the initial treatment and recurrence phases of the AL group were compared,P>0.05. The 5-year survival rate of AL patients with high levels of hs-CRP was 32.29% (31/96), which was lower than 42.59% (23/54) of patients with low levels of hs-CRP (χ²=6.764, P=0.009); the survival rate of people with high LDH level was 22.78% (18/79), and the survival rate of people with low LDH level was 50.70% (36/71). The above two was compared, χ ²=21.010, P=0.001.

The levels of serum hs-CRP and LDH in AL patients during initial treatment period and recurrence period were higher than those during remission period. The 5-year survival rate in patients with high levels of serum hs-CRP and LDH is lower than that with low levels.

Acute leukemia; Hypersensitive C-reactive protein; Lactate dehydrogenase